{"entity":{"id":"nct06961201","kind":"trial","name":"Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cache","aka":[],"tldr":"A phase 3 trial in lung cancer, run by Changchun GeneScience Pharmaceutical Co., Ltd., not yet recruiting.","summary":"Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase is a phase 3, randomised interventional study registered as NCT06961201 by Changchun GeneScience Pharmaceutical Co., Ltd., with a registry enrolment figure of 94 participants, started 2025-05-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: Nano-crystalline Megestrol Acetate Oral Suspension; standard treatment. Conditions listed: Extensive-stage Small Cell Lung Cancer (ES-SCLC); The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy. Primary outcome: The proportion of subjects with improved appetite based on A/CS-12 assessment; The proportion of subjects with a relative increase in BMI from baseline. Lung eligibility wording from the registry: \"* Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC) (according to the Veterans Administration Lung Study Group (VALG) staging system)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06961201","url":"https://clinicaltrials.gov/study/NCT06961201"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["extensive-stage-sclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["changchun-genescience"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06961201","phase":"3","setting":"A Prospective, Randomized, Parallel-controlled Clinical Study of Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer (ES-SCLC) in the Cachexia Phase","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","enrolled":94,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06961201/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"}],"company":[{"id":"changchun-genescience","kind":"company","name":"Changchun GeneScience Pharmaceutical","route":"/companies/changchun-genescience/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}